HR+HER2- tumors, categorized as Luminal A and B, generally display a lower relapse rate within 3–4 years after diagnosis as compared to triple-negative and HER2 enriched breast cancer (Cossetti et al, 2015). This evidence concerns the gene ERBB2 and breast carcinoma.